NASDAQ:ALPN - Alpine Immune Sciences Stock Price, Forecast & News

Alpine Immune Sciences trades on the NASDAQ under the ticker symbol "ALPN."

Alpine Immune Sciences Inc (NASDAQ:ALPN) issued its quarterly earnings data on Wednesday, November, 13th. The biotechnology company reported ($0.62) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.68) by $0.06. The biotechnology company had revenue of $0.29 million for the quarter, compared to analysts' expectations of $0.38 million. View Alpine Immune Sciences' Earnings History.

Alpine Immune Sciences is scheduled to release their next quarterly earnings announcement on Monday, March 16th 2020. View Earnings Estimates for Alpine Immune Sciences.

2 equities research analysts have issued twelve-month price objectives for Alpine Immune Sciences' stock. Their forecasts range from $8.00 to $13.00. On average, they anticipate Alpine Immune Sciences' share price to reach $10.50 in the next twelve months. This suggests a possible upside of 228.1% from the stock's current price. View Analyst Price Targets for Alpine Immune Sciences.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Alpine Immune Sciences in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Alpine Immune Sciences.

Media headlines about ALPN stock have been trending positive on Thursday, according to InfoTrie Sentiment. The research firm scores the sentiment of media coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Alpine Immune Sciences earned a news sentiment score of 2.2 on InfoTrie's scale. They also assigned headlines about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an effect on the company's share price in the next few days. View News Stories for Alpine Immune Sciences.

Alpine Immune Sciences saw a decline in short interest in the month of February. As of February 14th, there was short interest totalling 10,100 shares, a decline of 57.4% from the January 30th total of 23,700 shares. Based on an average daily trading volume, of 17,800 shares, the short-interest ratio is presently 0.6 days. Approximately 0.1% of the shares of the stock are short sold. View Alpine Immune Sciences' Current Options Chain.

Some companies that are related to Alpine Immune Sciences include XOMA (XOMA), Kala Pharmaceuticals (KALA), Sol Gel Technologies (SLGL), Theratechnologies (THERF), Agile Therapeutics (AGRX), Aeglea Bio Therapeutics (AGLE), Arcturus Therapeutics (ARCT), Genprex (GNPX), LifeVantage (LFVN), Abeona Therapeutics (ABEO), Neptune Wellness Solutions (NEPT), MediciNova (MNOV), Kezar Life Sciences (KZR), Athersys (ATHX) and Theratechnologies (THTX).

Based on aggregate information from My MarketBeat watchlists, some companies that other Alpine Immune Sciences investors own include Viking Therapeutics (VKTX), Abeona Therapeutics (ABEO), Melinta Therapeutics (MLNT), Energy Transfer LP Unit (ET), CymaBay Therapeutics (CBAY), Corbus Pharmaceuticals (CRBP), Progenics Pharmaceuticals (PGNX), GALAPAGOS NV/S (GLPG), AEterna Zentaris (AEZS) and Ardelyx (ARDX).

Alpine Immune Sciences' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Renaissance Technologies LLC (0.69%) and Alpine Woods Capital Investors LLC (0.06%). Company insiders that own Alpine Immune Sciences stock include James N Topper, James Paul Rickey, Mitchell Gold and Tiger Management LLC. View Institutional Ownership Trends for Alpine Immune Sciences.

ALPN stock was sold by a variety of institutional investors in the last quarter, including Alpine Woods Capital Investors LLC. View Insider Buying and Selling for Alpine Immune Sciences.

ALPN stock was purchased by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC. Company insiders that have bought Alpine Immune Sciences stock in the last two years include James N Topper, James Paul Rickey and Mitchell Gold. View Insider Buying and Selling for Alpine Immune Sciences.

Shares of ALPN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of ALPN stock can currently be purchased for approximately $3.20.

Alpine Immune Sciences has a market capitalization of $59.49 million and generates $700,000.00 in revenue each year. The biotechnology company earns $-36,490,000.00 in net income (profit) each year or ($2.63) on an earnings per share basis. Alpine Immune Sciences employs 48 workers across the globe.View Additional Information About Alpine Immune Sciences.

The official website for Alpine Immune Sciences is http://www.alpineimmunesciences.com/.

Alpine Immune Sciences' mailing address is 201 Elliott Avenue West Suite 230, Seattle WA, 98119. The biotechnology company can be reached via phone at 206-788-4545 or via email at [email protected]